Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...
Ended 2024 with $5.9M in cash and cash equivalents. The company believes it has sufficient capital resources to fund its operations into late ...
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...
Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the ...
Hosted on MSN1mon
Imunon director Donald Braun acquires $29,480 worth of sharesDonald P. Braun, a director at Imunon, Inc. (NASDAQ:IMNN), recently purchased 25,000 shares of the company's common stock, according to a filing with the Securities and Exchange Commission.
LAWRENCEVILLE, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company entering a pivotal Phase 3 trial of its DNA-mediated immunotherapy, today announced new ...
New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also ...
(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, on Wednesday shared promising new data from its Phase 2 OVATION 2 Study of IMNN-001, an investigational immunotherapy for ...
LAWRENCEVILLE, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company entering a pivotal Phase 3 trial of its DNA-mediated immunotherapy, today announced new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback